HomeCompareKREVF vs JNJ

KREVF vs JNJ: Dividend Comparison 2026

KREVF yields 5.96% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KREVF wins by $17007.66M in total portfolio value
10 years
KREVF
KREVF
● Live price
5.96%
Share price
$0.68
Annual div
$0.04
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17007.69M
Annual income
$16,476,820,731.62
Full KREVF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — KREVF vs JNJ

📍 KREVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKREVFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KREVF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KREVF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KREVF
Annual income on $10K today (after 15% tax)
$506.81/yr
After 10yr DRIP, annual income (after tax)
$14,005,297,621.88/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, KREVF beats the other by $14,005,293,635.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KREVF + JNJ for your $10,000?

KREVF: 50%JNJ: 50%
100% JNJ50/50100% KREVF
Portfolio after 10yr
$8503.86M
Annual income
$8,238,412,710.51/yr
Blended yield
96.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KREVF
No analyst data
Altman Z
0.7
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KREVF buys
0
JNJ buys
0
No recent congressional trades found for KREVF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKREVFJNJ
Forward yield5.96%2.13%
Annual dividend / share$0.04$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$17007.69M$30.3K
Annual income after 10y$16,476,820,731.62$4,689.40
Total dividends collected$16970.89M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KREVF vs JNJ ($10,000, DRIP)

YearKREVF PortfolioKREVF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,892$1,192.50$10,592$272.30+$1.3KKREVF
2$15,376$2,650.80$11,289$357.73+$4.1KKREVF
3$22,858$6,405.99$12,123$472.89+$10.7KKREVF
4$42,259$17,800.63$13,141$629.86+$29.1KKREVF
5$106,729$61,511.86$14,408$846.81+$92.3KKREVF
6$404,582$290,381.96$16,021$1,151.60+$388.6KKREVF
7$2,490,407$2,057,504.31$18,122$1,588.22+$2.47MKREVF
8$26,337,611$23,672,875.85$20,930$2,228.20+$26.32MKREVF
9$496,135,430$467,954,186.07$24,792$3,191.91+$496.11MKREVF
10$17,007,685,642$16,476,820,731.62$30,274$4,689.40+$17007.66MKREVF

KREVF vs JNJ: Complete Analysis 2026

KREVFStock

Listed by way of an introduction on 28 April 2006, Keppel REIT is one of Asia's leading REITs with a portfolio of Grade A commercial assets in key business districts pan-Asia. Keppel REIT's objective is to generate stable income and long-term growth for Unitholders by owning and investing in a portfolio of quality income-producing commercial real estate and real estate-related assets in Singapore and pan-Asia. The REIT has assets under management of over $8 billion in Singapore, key Australian cities of Sydney, Melbourne, Brisbane and Perth, as well as Seoul, South Korea. Keppel REIT is sponsored by Keppel Land Limited, one of Asia's leading property companies. It is managed by Keppel REIT Management Limited, a wholly-owned subsidiary of Keppel Capital Holdings Pte Ltd (Keppel Capital). Keppel Capital is a premier asset manager in Asia with a diversified portfolio in real estate, infrastructure and data centre properties in key global markets.

Full KREVF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this KREVF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KREVF vs SCHDKREVF vs JEPIKREVF vs OKREVF vs KOKREVF vs MAINKREVF vs ABBVKREVF vs MRKKREVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.